Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
28
RDHL Quote, Financials, Valuation and Earnings
Last price:
$1.14
Seasonality move
:
-10.63%
Day range:
$1.15 - $1.21
52-week range:
$1.01 - $7.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
1.10x
Volume:
72.5K
Avg. volume:
74.8K
1-year change:
-81.89%
Market cap:
$3.8M
Revenue:
$8.1M
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, RedHill Biopharma Ltd. has 86856.52% upside to fair value with a price target of -- per share.
RDHL vs. S&P 500
-
Over the past 5 trading days, RedHill Biopharma Ltd. has underperformed the S&P 500 by -2.93% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
RedHill Biopharma Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
RedHill Biopharma Ltd. revenues have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter RedHill Biopharma Ltd. reported revenues of --.
Earnings Growth
-
RedHill Biopharma Ltd. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter RedHill Biopharma Ltd. reported earnings per share of --.
Enterprise value:
-10M
EV / Invested capital:
--
Price / LTM sales:
0.00x
EV / EBIT:
-0.09x
EV / Revenue:
-0.28x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-0.04x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Income Statement | ||||||
| Revenue | $84.7M | $75.1M | $35.5M | $18.1M | $1.8M | |
| Gross Profit | $42.8M | $31.3M | $14.1M | $9.2M | -$133.5K | |
| Operating Income | -$77.4M | -$64M | -$35.1M | -$9.1M | -$8.2M | |
| EBITDA | -$67.6M | -$46.4M | -$29.5M | -$7.2M | -$7.1M | |
| Diluted EPS | -$2,295.25 | -$1,543.80 | -$78.99 | -$203.67 | $4.75 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $70.5M | $89.2M | $85.9M | -- | $11.9M | |
| Total Assets | $180.2M | $181.2M | $158.9M | -- | $18M | |
| Current Liabilities | $73.2M | $81.5M | $197.5M | -- | $22.2M | |
| Total Liabilities | $166.4M | $172.3M | $207.3M | -- | $22.7M | |
| Total Equity | $13.9M | $8.9M | -$48.4M | -- | -$4.7M | |
| Total Debt | $86.9M | $87.8M | $7.5M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$52.9M | -$54.7M | -$26M | -$16.5M | -$10.5M | |
| Cash From Investing | $5.9M | $3.2M | -$27.2K | -$215.6K | -$6.9K | |
| Cash From Financing | $76.6M | $26.7M | -$550.2K | $14.9M | -$1.9M | |
| Free Cash Flow | -$54M | -$54.9M | -$26M | -$16.6M | -$10.5M | |
RDHL
Sector
Market Cap
$3.8M
$27.8M
Price % of 52-Week High
16.43%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.55%
1-Year Price Total Return
-81.89%
-17.47%
Beta (5-Year)
4.831
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.17
200-day SMA
Sell
Level
$1.77
Bollinger Bands (100)
Sell
Level
1.11 - 1.71
Chaikin Money Flow
Sell
Level
-171.6K
20-day SMA
Sell
Level
$1.18
Relative Strength Index (RSI14)
Sell
Level
44.86
ADX Line
Sell
Level
25.58
Williams %R
Neutral
Level
-68.75
50-day SMA
Sell
Level
$1.26
MACD (12, 26)
Buy
Level
0.29
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Sell
Level
-90.5K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-34.4637)
Sell
CA Score
(Annual)
Level (-5.6004)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (7.3954)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
Stock Forecast FAQ
In the current month, RDHL has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RDHL average analyst price target in the past 3 months is --.
-
Where Will RedHill Biopharma Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that RedHill Biopharma Ltd. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About RedHill Biopharma Ltd.?
Analysts are divided on their view about RedHill Biopharma Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that RedHill Biopharma Ltd. is a Sell and believe this share price will drop from its current level to --.
-
What Is RedHill Biopharma Ltd.'s Price Target?
The price target for RedHill Biopharma Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RDHL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for RedHill Biopharma Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of RDHL?
You can purchase shares of RedHill Biopharma Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase RedHill Biopharma Ltd. shares.
-
What Is The RedHill Biopharma Ltd. Share Price Today?
RedHill Biopharma Ltd. was last trading at $1.14 per share. This represents the most recent stock quote for RedHill Biopharma Ltd.. Yesterday, RedHill Biopharma Ltd. closed at $1.15 per share.
-
How To Buy RedHill Biopharma Ltd. Stock Online?
In order to purchase RedHill Biopharma Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get RDHL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RDHL
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
1.10x
1.82x
Price / LTM sales
0.00x
1.60x
Growth Metrics
RDHL
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.88%
Revenue (5-year growth)
5.07%
6.5%
Earnings forecast
--
-$0.21
Profitability
RDHL
Sector
Profitability FY 2024
$4.9M
$3.5M
Return on invested capital
--
-31.77%
Return on assets
--
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Apr
25
Next Earnings Date
Dec
26
Estimated Next Earnings Date
Mar
27
Balance Sheet
RDHL
Sector
Total cash
$7.3M
$26.3M
Short term investments
--
$25.7M
Total assets
$18M
$78M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 0.72% over the past day.
Buy
64
ZCSH alert for Dec 26
Grayscale Zcash Trust (ZEC) [ZCSH] is down 1.79% over the past day.
Buy
66
ASTS alert for Dec 26
AST Spacemobile, Inc. [ASTS] is down 7.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
